You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameValsartan
Accession NumberDB00177  (APRD00133)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionValsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Structure
Thumb
Synonyms
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
Diovan
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Valsartantablet80 mgoralActavis Pharma Company2011-02-16Not applicableCanada
Act Valsartantablet160 mgoralActavis Pharma Company2011-02-16Not applicableCanada
Act Valsartantablet320 mgoralActavis Pharma Company2011-02-16Not applicableCanada
Act Valsartantablet40 mgoralActavis Pharma Company2011-02-16Not applicableCanada
Auro-valsartantablet40 mgoralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartantablet80 mgoralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartantablet320 mgoralAuro Pharma Inc2014-02-06Not applicableCanada
Auro-valsartantablet160 mgoralAuro Pharma Inc2014-02-06Not applicableCanada
Ava-valsartantablet80 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-valsartantablet160 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-valsartantablet320 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-valsartantablet40 mgoralAvanstra Inc2011-08-182014-08-21Canada
Diovantablet80 mg/1oralNovartis Pharmaceuticals Corporation2001-07-01Not applicableUs
Diovantablet160 mg/1oralbryant ranch prepack2001-07-01Not applicableUs
Diovantablet160 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-28Not applicableUs
Diovantablet320 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-28Not applicableUs
Diovantablet160 mg/1oralPd Rx Pharmaceuticals, Inc.2001-07-01Not applicableUs
Diovantablet40 mg/1oralCarilion Materials Management2001-07-01Not applicableUs
Diovantablet320 mg/1oralPhysicians Total Care, Inc.2007-09-17Not applicableUs
Diovantablet80 mg/1oralRebel Distributors Corp2001-07-01Not applicableUs
Diovantablet80 mg/1oralAphena Pharma Solutions Tennessee, Llc2001-07-01Not applicableUs
Diovantablet80 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-02-28Not applicableUs
Diovantablet160 mg/1oralNovartis Pharmaceuticals Corporation2001-07-01Not applicableUs
Diovantablet80 mg/1oralREMEDYREPACK INC.2014-01-09Not applicableUs
Diovantablet80 mg/1oralPd Rx Pharmaceuticals, Inc.2001-07-01Not applicableUs
Diovantablet40 mg/1oralPhysicians Total Care, Inc.2009-01-02Not applicableUs
Diovantablet40 mgoralNovartis Pharmaceuticals Canada Inc2005-11-01Not applicableCanada
Diovantablet160 mg/1oralCardinal Health2001-07-01Not applicableUs
Diovantablet160 mg/1oralRebel Distributors Corp2001-07-01Not applicableUs
Diovantablet160 mg/1oralAphena Pharma Solutions Tennessee, Llc2001-07-01Not applicableUs
Diovantablet160 mg/1oralPhysicians Total Care, Inc.2008-02-28Not applicableUs
Diovantablet320 mg/1oralNovartis Pharmaceuticals Corporation2001-07-01Not applicableUs
Diovantablet160 mg/1oralREMEDYREPACK INC.2013-09-11Not applicableUs
Diovantablet320 mg/1oralPd Rx Pharmaceuticals, Inc.2001-07-01Not applicableUs
Diovantablet80 mg/1oralCardinal Health2001-07-01Not applicableUs
Diovantablet320 mgoralNovartis Pharmaceuticals Canada Inc2007-02-14Not applicableCanada
Diovantablet320 mg/1oralCardinal Health2001-07-01Not applicableUs
Diovantablet320 mg/1oralRebel Distributors Corp2001-07-01Not applicableUs
Diovantablet40 mg/1oralNovartis Pharmaceuticals Corporation2001-07-01Not applicableUs
Diovantablet80 mg/1oralCarilion Materials Management2001-07-01Not applicableUs
Diovantablet80 mg/1oralPhysicians Total Care, Inc.2010-01-06Not applicableUs
Diovantablet40 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-15Not applicableUs
Diovantablet80 mg/1oralbryant ranch prepack2001-07-01Not applicableUs
Diovan 160mgcapsule160 mgoralNovartis Pharmaceuticals Canada Inc1997-12-15Not applicableCanada
Diovan 160mg Tabletstablet160 mgoralNovartis Pharmaceuticals Canada Inc2003-01-24Not applicableCanada
Diovan 80mgcapsule80 mgoralNovartis Pharmaceuticals Canada Inc1997-12-15Not applicableCanada
Diovan 80mg Tabletstablet80 mgoralNovartis Pharmaceuticals Canada Inc2003-01-24Not applicableCanada
Dom-valsartantablet160 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-valsartantablet320 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-valsartantablet40 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-valsartantablet80 mgoralDominion Pharmacal2014-02-03Not applicableCanada
Mylan-valsartantablet320 mgoralMylan Pharmaceuticals Ulc2012-04-27Not applicableCanada
Mylan-valsartantablet40 mgoralMylan Pharmaceuticals Ulc2012-04-27Not applicableCanada
Mylan-valsartantablet80 mgoralMylan Pharmaceuticals Ulc2012-04-27Not applicableCanada
Mylan-valsartantablet160 mgoralMylan Pharmaceuticals Ulc2012-04-27Not applicableCanada
Novo-valsartantablet160 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Novo-valsartantablet320 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Novo-valsartantablet40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Novo-valsartantablet80 mgoralTeva Canada LimitedNot applicableNot applicableCanada
PMS-valsartantablet40 mgoralPharmascience Inc2012-05-22Not applicableCanada
PMS-valsartantablet80 mgoralPharmascience Inc2012-05-22Not applicableCanada
PMS-valsartantablet160 mgoralPharmascience Inc2012-05-22Not applicableCanada
PMS-valsartantablet320 mgoralPharmascience Inc2012-05-22Not applicableCanada
Q-valsartantablet80 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-valsartantablet160 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-valsartantablet320 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-valsartantablet40 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-valsartantablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-02-16Not applicableCanada
Ran-valsartantablet80 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-02-16Not applicableCanada
Ran-valsartantablet160 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-02-16Not applicableCanada
Riva-valsartantablet160 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-valsartantablet320 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-valsartantablet40 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-valsartantablet80 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Sandoz Valsartantablet320 mgoralSandoz Canada Incorporated2011-01-27Not applicableCanada
Sandoz Valsartantablet40 mgoralSandoz Canada Incorporated2011-01-27Not applicableCanada
Sandoz Valsartantablet80 mgoralSandoz Canada Incorporated2011-01-27Not applicableCanada
Sandoz Valsartantablet160 mgoralSandoz Canada Incorporated2011-01-27Not applicableCanada
Teva-valsartantablet320 mgoralTeva Canada Limited2011-02-16Not applicableCanada
Teva-valsartantablet40 mgoralTeva Canada Limited2011-02-16Not applicableCanada
Teva-valsartantablet80 mgoralTeva Canada Limited2011-02-16Not applicableCanada
Teva-valsartantablet160 mgoralTeva Canada Limited2011-02-16Not applicableCanada
Valsartantablet40 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Valsartantablet320 mg/1oralSandoz Inc2014-07-07Not applicableUs
Valsartantablet160 mg/1oralCardinal Health2014-07-07Not applicableUs
Valsartantablet320 mgoralPro Doc Limitee2011-05-30Not applicableCanada
Valsartantablet40 mgoralSanis Health Inc2012-07-20Not applicableCanada
Valsartantablet320 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Valsartantablet80 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Valsartantablet40 mg/1oralSandoz Inc2014-07-07Not applicableUs
Valsartantablet40 mgoralPro Doc Limitee2011-05-30Not applicableCanada
Valsartantablet80 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Valsartantablet80 mg/1oralCardinal Health2014-07-07Not applicableUs
Valsartantablet80 mgoralSanis Health Inc2012-07-20Not applicableCanada
Valsartantablet320 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Valsartantablet40 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Valsartantablet80 mg/1oralSandoz Inc2014-07-07Not applicableUs
Valsartantablet80 mgoralPro Doc Limitee2011-05-30Not applicableCanada
Valsartantablet160 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Valsartantablet160 mgoralSanis Health Inc2012-07-20Not applicableCanada
Valsartantablet80 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Valsartantablet40 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Valsartantablet160 mg/1oralSandoz Inc2014-07-07Not applicableUs
Valsartantablet160 mgoralPro Doc Limitee2011-05-30Not applicableCanada
Valsartantablet320 mgoralSanis Health Inc2012-07-20Not applicableCanada
Valsartantablet160 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Valsartantablet160 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-valsartantablet320 mgoralApotex Inc2012-07-12Not applicableCanada
Apo-valsartantablet40 mgoralApotex Inc2012-07-12Not applicableCanada
Apo-valsartantablet80 mgoralApotex Inc2012-07-12Not applicableCanada
Apo-valsartantablet160 mgoralApotex Inc2012-07-12Not applicableCanada
Valsartantablet, film coated160 mg/1oralCamber Pharmaceuticals, Inc.2015-01-05Not applicableUs
Valsartantablet, film coated320 mg/1oralMylan Pharmaceuticals Inc.2015-01-05Not applicableUs
Valsartantablet80 mg/1oralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
Valsartantablet320 mg/1oralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
Valsartantablet320 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-01-17Not applicableUs
Valsartantablet80 mg/1oralLupin Pharmaceuticals, Inc.2015-01-05Not applicableUs
Valsartantablet320 mg/1oralQualitest Pharmaceuticals2015-01-06Not applicableUs
Valsartantablet, film coated40 mg/1oralTeva Pharmaceuticals USA Inc2015-01-05Not applicableUs
Valsartantablet, film coated160 mg/1oralAv Kare, Inc.2015-01-29Not applicableUs
Valsartantablet, film coated320 mg/1oralOhm Laboratories Inc.2014-07-07Not applicableUs
Valsartantablet, film coated160 mg/1oralAv Kare, Inc.2015-11-12Not applicableUs
Valsartantablet, film coated320 mg/1oralActavis Pharma, Inc.2015-01-05Not applicableUs
Valsartantablet, film coated160 mg/1oralNorthwind Pharmaceuticals2015-01-07Not applicableUs
Valsartantablet, film coated80 mg/1oralAurobindo Pharma Limited2015-01-05Not applicableUs
Valsartantablet320 mg/1oralTorrent Pharmaceuticals Limited2015-01-05Not applicableUs
Valsartantablet, film coated40 mg/1oralMylan Pharmaceuticals Inc.2015-01-05Not applicableUs
Valsartantablet160 mg/1oralSolco Healthcare US, LLC2015-08-31Not applicableUs
Valsartantablet40 mg/1oralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
Valsartantablet40 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-01-17Not applicableUs
Valsartantablet, film coated80 mg/1oralAmerican Health Packaging2015-02-20Not applicableUs
Valsartantablet, film coated320 mg/1oralCamber Pharmaceuticals, Inc.2015-01-05Not applicableUs
Valsartantablet, film coated40 mg/1oralActavis Pharma, Inc.2015-01-05Not applicableUs
Valsartantablet160 mg/1oralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
Valsartantablet, film coated80 mg/1oralTeva Pharmaceuticals USA Inc2015-01-05Not applicableUs
Valsartantablet, film coated320 mg/1oralAv Kare, Inc.2015-01-29Not applicableUs
Valsartantablet, film coated160 mg/1oralPhysicians Total Care, Inc.2015-01-05Not applicableUs
Valsartantablet160 mg/1oralLupin Pharmaceuticals, Inc.2015-01-05Not applicableUs
Valsartantablet40 mg/1oralTorrent Pharmaceuticals Limited2015-01-05Not applicableUs
Valsartantablet, film coated320 mg/1oralAv Kare, Inc.2015-11-12Not applicableUs
Valsartantablet40 mg/1oralQualitest Pharmaceuticals2015-01-06Not applicableUs
Valsartantablet, film coated40 mg/1oralOhm Laboratories Inc.2014-07-07Not applicableUs
Valsartantablet, film coated160 mg/1oralAurobindo Pharma Limited2015-01-05Not applicableUs
Valsartantablet320 mg/1oralProficient Rx LP2015-08-31Not applicableUs
Valsartantablet, film coated40 mg/1oralCamber Pharmaceuticals, Inc.2015-01-05Not applicableUs
Valsartantablet, film coated80 mg/1oralMylan Pharmaceuticals Inc.2015-01-05Not applicableUs
Valsartantablet320 mg/1oralSolco Healthcare US, LLC2015-08-31Not applicableUs
Valsartantablet80 mg/1oralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
Valsartantablet80 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-01-17Not applicableUs
Valsartantablet, film coated80 mg/1oralActavis Pharma, Inc.2015-01-05Not applicableUs
Valsartantablet320 mg/1oralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
Valsartantablet, film coated160 mg/1oralAmerican Health Packaging2015-02-20Not applicableUs
Valsartantablet, film coated40 mg/1oralAv Kare, Inc.2015-11-12Not applicableUs
Valsartantablet, film coated160 mg/1oralTeva Pharmaceuticals USA Inc2015-01-05Not applicableUs
Valsartantablet40 mg/1oralSolco Healthcare US, LLC2015-08-31Not applicableUs
Valsartantablet, film coated320 mg/1oralPhysicians Total Care, Inc.2015-01-05Not applicableUs
Valsartantablet320 mg/1oralLupin Pharmaceuticals, Inc.2015-01-05Not applicableUs
Valsartantablet80 mg/1oralTorrent Pharmaceuticals Limited2015-01-05Not applicableUs
Valsartantablet, film coated40 mg/1oralAv Kare, Inc.2015-01-29Not applicableUs
Valsartantablet80 mg/1oralQualitest Pharmaceuticals2015-01-06Not applicableUs
Valsartantablet, film coated80 mg/1oralOhm Laboratories Inc.2014-07-07Not applicableUs
Valsartantablet, film coated320 mg/1oralAurobindo Pharma Limited2015-01-05Not applicableUs
Valsartantablet320 mg/1oralLake Erie Medical DBA Quality Care Products LLC2015-08-31Not applicableUs
Valsartantablet, film coated80 mg/1oralCamber Pharmaceuticals, Inc.2015-01-05Not applicableUs
Valsartantablet, film coated160 mg/1oralMylan Pharmaceuticals Inc.2015-01-05Not applicableUs
Valsartantablet40 mg/1oralAlembic Pharmaceuticals Limited2015-01-06Not applicableUs
Valsartantablet160 mg/1oralJubilant Cadista Pharmaceuticals Inc.2014-12-23Not applicableUs
Valsartantablet160 mg/1oralAmneal Pharmaceuticals of New York, LLC2016-01-17Not applicableUs
Valsartantablet, film coated160 mg/1oralActavis Pharma, Inc.2015-01-05Not applicableUs
Valsartantablet, film coated80 mg/1oralNorthwind Pharmaceuticals, LLC2014-11-13Not applicableUs
Valsartantablet, film coated40 mg/1oralAurobindo Pharma Limited2015-01-05Not applicableUs
Valsartantablet, film coated80 mg/1oralAv Kare, Inc.2015-11-12Not applicableUs
Valsartantablet160 mg/1oralTorrent Pharmaceuticals Limited2015-01-05Not applicableUs
Valsartantablet, film coated320 mg/1oralTeva Pharmaceuticals USA Inc2015-01-05Not applicableUs
Valsartantablet80 mg/1oralSolco Healthcare US, LLC2015-08-31Not applicableUs
Valsartantablet, film coated80 mg/1oralPhysicians Total Care, Inc.2015-01-05Not applicableUs
Valsartantablet, film coated80 mg/1oralAvera Mc Kennan Hospital2015-05-20Not applicableUs
Valsartantablet, film coated80 mg/1oralAv Kare, Inc.2015-01-29Not applicableUs
Valsartantablet160 mg/1oralQualitest Pharmaceuticals2015-01-06Not applicableUs
Valsartantablet, film coated160 mg/1oralOhm Laboratories Inc.2014-07-07Not applicableUs
Valsartantablet40 mg/1oralLupin Pharmaceuticals, Inc.2015-01-05Not applicableUs
Valsartantablet160 mg/1oralLake Erie Medical DBA Quality Care Products LLC2015-08-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Amlodipine and ValsartanTeva Pharmaceuticals USA Inc
Amlodipine Besylate and ValsartanMylan Pharmaceuticals Inc.
Amlodipine, Valsartan and HydrochlorothiazideTorrent Pharmaceuticals Limited
Amlodipine, Valsartan, and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Amlodipine, Valsartan, HydrochlorothiazideSandoz Inc
Apo-valsartan/hctzApotex Inc
Auro-valsartan HctAuro Pharma Inc
Ava-valsartan HctAvanstra Inc
Diovan HctNovartis Pharmaceuticals Corporation
Diovan-hctNovartis Pharmaceuticals Canada Inc
EntrestoNovartis Pharmaceuticals Corporation
ExforgeNovartis Pharmaceuticals Corporation
Exforge HctNovartis Pharmaceuticals Corporation
Mylan-valsartan HctzMylan Pharmaceuticals Ulc
Novo-valsartan/hctzTeva Canada Limited
PMS-valsartan-hctzPharmascience Inc
Q-valsartan HctzQd Pharmaceuticals Ulc
Sandoz Valsartan HctSandoz Canada Incorporated
Teva-valsartan/hctzTeva Canada Limited
Valsartan and HydrochlorothiazideMylan Pharmaceuticals Inc.
Valsartan HctSanis Health Inc
Valsartan HctzNorthwind Pharmaceuticals
Valsartan-hctzPro Doc Limitee
SaltsNot Available
Categories
UNII80M03YXJ7I
CAS number137862-53-4
WeightAverage: 435.5188
Monoisotopic: 435.227039819
Chemical FormulaC24H29N5O3
InChI KeyInChIKey=ACWBQPMHZXGDFX-QFIPXVFZSA-N
InChI
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
IUPAC Name
(2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
SMILES
CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • N-acyl-aliphatic-alpha amino acid
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Biphenyl
  • N-acyl-l-alpha-amino acid
  • Alpha-amino acid or derivatives
  • Phenylmethylamine
  • Benzylamine
  • Benzenoid
  • N-acyl-amine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
PharmacodynamicsValsartan belongs to a class of antihypertensive agents called angiotensin II receptor blockers (ARBs). Valsartan is a specific and selective type-1 angiotensin II receptor (AT1) antagonist which blocks the blood pressure increasing effects angiotensin II via the renin-angiotensin-aldosterone system (RAAS). RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: AT1 and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.
Mechanism of actionValsartan is an ARB that selectively inhibits the binding of angiotensin II to AT1, which is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in a decrease in vascular resistance and blood pressure. Valsartan is selective for AT1 and has virtually no affinity for AT2. Inhibition of aldosterone secretion may inhibit sodium and water reabsorption in the kidneys while decreasing potassium excretion. The primary metabolite of valsartan, valeryl 4-hydroxy valsartan, has no pharmacological activity.
Related Articles
AbsorptionAbsolute bioavailability = 23% with high variability
Volume of distribution
  • 17 L (low tissue distribution)
Protein binding94 - 97% bound to serum proteins, primarily serum albumin
Metabolism

Valsartan is excreted largely as unchanged drug (80%) and is minimally metabolized in humans. The primary circulating metabolite, 4-OH-valsartan, is pharmacologically inactive and produced CYP2C9. 4-OH-valsartan accounts for approximately 9% of the circulating dose of valsartan. Although valsartan is metabolized by CYP2C9, CYP-mediated drug-drug interactions between valsartan and other drugs is unlikely.

SubstrateEnzymesProduct
Valsartan
4-HydroxyvalsartanDetails
Route of elimination83% of absorbed valsartan is excreted in feces and 13% is excreted in urine, primarily as unchanged drug
Half lifeThe initial phase t1/2 α is < 1 hour while the terminal phase t1/2 β is 5-9 hours.
Clearance
  • 2 L/h [IV administration]
  • 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Valsartan Action PathwayDrug actionSMP00165
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9956
Blood Brain Barrier-0.8032
Caco-2 permeable-0.6912
P-glycoprotein substrateSubstrate0.685
P-glycoprotein inhibitor INon-inhibitor0.5548
P-glycoprotein inhibitor IINon-inhibitor0.5966
Renal organic cation transporterNon-inhibitor0.8646
CYP450 2C9 substrateNon-substrate0.7722
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5073
CYP450 1A2 substrateNon-inhibitor0.8707
CYP450 2C9 inhibitorNon-inhibitor0.5398
CYP450 2D6 inhibitorNon-inhibitor0.8816
CYP450 2C19 inhibitorInhibitor0.5539
CYP450 3A4 inhibitorNon-inhibitor0.5521
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5618
Ames testNon AMES toxic0.6384
CarcinogenicityNon-carcinogens0.645
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6518 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9766
hERG inhibition (predictor II)Non-inhibitor0.7388
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Novartis Corporation
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral160 mg/1
Tabletoral320 mg/1
Tabletoral320 mg
Tabletoral40 mg
Tabletoral40 mg/1
Tabletoral80 mg/1
Capsuleoral160 mg
Tabletoral160 mg
Capsuleoral80 mg
Tabletoral80 mg
Tablet, film coatedoral
Tablet, film coatedoral160 mg/1
Tablet, film coatedoral320 mg/1
Tablet, film coatedoral40 mg/1
Tablet, film coatedoral80 mg/1
Prices
Unit descriptionCostUnit
Diovan hct 320-25 mg tablet4.63USD tablet
Diovan hct 320-12.5 mg tablet4.1USD tablet
Diovan hct 160-25 mg tablet3.66USD tablet
Diovan hct 160-12.5 mg tablet3.27USD tablet
Diovan 320 mg tablet3.17USD tablet
Diovan hct 80-12.5 mg tablet3.0USD tablet
Diovan 160 mg tablet2.42USD tablet
Diovan 80 mg tablet2.33USD tablet
Diovan 40 mg tablet2.32USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2036427 No1998-12-292011-02-15Canada
CA2259148 No2009-09-292017-06-18Canada
US5399578 No1995-03-212012-03-21Us
US5559111 No1998-07-212018-07-21Us
US5972990 Yes1997-04-262017-04-26Us
US6294197 Yes1997-12-182017-12-18Us
US6395728 No1999-07-082019-07-08Us
US7468390 No2003-11-272023-11-27Us
US8101599 No2003-05-162023-05-16Us
US8101659 No2003-01-142023-01-14Us
US8168616 No2006-07-032026-07-03Us
US8404744 No2003-01-142023-01-14Us
US8475839 Yes2003-11-162023-11-16Us
US8796331 No2003-01-142023-01-14Us
US8877938 No2007-05-272027-05-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point116-117 °CNot Available
logP5.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0234 mg/mLALOGPS
logP3.68ALOGPS
logP5.27ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)4.37ChemAxon
pKa (Strongest Basic)-0.11ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area112.07 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity134.77 m3·mol-1ChemAxon
Polarizability47.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Zvi Harel, Igor Rukhman, “Process for the preparation of valsartan.” U.S. Patent US20050010053, issued January 13, 2005.

US20050010053
General References
  1. Bader, M. (2004). Renin-angiotensin-aldosterone system. In Encyclopedic reference of molecular pharmacology (pp. 810-814). Berlin: Springer. [ISBN:9783540298328 ]
External Links
ATC CodesC09DX02C10BX10C09DB08C09DB01C09DX01C09DA03C09DX04C09CA03
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (237 KB)
MSDSDownload (36.2 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Valsartan.
AbirateroneThe metabolism of Valsartan can be decreased when combined with Abiraterone.
AcebutololValsartan may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Aceclofenac.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Valsartan.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Valsartan.
AcetazolamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Valsartan is combined with Adapalene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.
AlfuzosinAlfuzosin may increase the hypotensive activities of Valsartan.
AliskirenValsartan may increase the hypotensive activities of Aliskiren.
AlosetronThe metabolism of Alosetron can be decreased when combined with Valsartan.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Valsartan.
AlprenololValsartan may increase the hypotensive activities of Alprenolol.
AmbrisentanValsartan may increase the hypotensive activities of Ambrisentan.
AmifostineValsartan may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Valsartan is combined with Amiloride.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Valsartan.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Valsartan.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Valsartan.
AmlodipineValsartan may increase the hypotensive activities of Amlodipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Valsartan.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Valsartan.
Amyl NitriteThe risk or severity of adverse effects can be increased when Valsartan is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Valsartan is combined with Antipyrine.
ApixabanThe metabolism of Apixaban can be decreased when combined with Valsartan.
ApraclonidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Valsartan is combined with Apremilast.
AprepitantThe metabolism of Valsartan can be increased when combined with Aprepitant.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Valsartan.
ArdeparinArdeparin may increase the hyperkalemic activities of Valsartan.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Valsartan.
AripiprazoleAripiprazole may increase the hypotensive activities of Valsartan.
ArtemetherThe metabolism of Artemether can be decreased when combined with Valsartan.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Valsartan.
AtenololValsartan may increase the hypotensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Valsartan is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Valsartan is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Valsartan.
BemiparinBemiparin may increase the hyperkalemic activities of Valsartan.
BenazeprilValsartan may increase the hypotensive activities of Benazepril.
BendroflumethiazideValsartan may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Valsartan.
BenoxaprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Benoxaprofen.
BepridilValsartan may increase the hypotensive activities of Bepridil.
BetaxololValsartan may increase the hypotensive activities of Betaxolol.
BethanidineValsartan may increase the hypotensive activities of Bethanidine.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Valsartan.
BimatoprostValsartan may increase the hypotensive activities of Bimatoprost.
BisoprololValsartan may increase the hypotensive activities of Bisoprolol.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Valsartan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Valsartan.
BosentanBosentan may increase the hypotensive activities of Valsartan.
BretyliumValsartan may increase the hypotensive activities of Bretylium.
BrimonidineValsartan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Valsartan.
BromfenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Bromfenac.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Valsartan.
BumetanideThe risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide.
BupranololValsartan may increase the hypotensive activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Valsartan.
BupropionThe metabolism of Bupropion can be decreased when combined with Valsartan.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Valsartan.
CaffeineThe metabolism of Caffeine can be decreased when combined with Valsartan.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Valsartan.
CanagliflozinThe risk or severity of adverse effects can be increased when Valsartan is combined with Canagliflozin.
CandesartanValsartan may increase the hypotensive activities of Candesartan.
CandoxatrilValsartan may increase the hypotensive activities of Candoxatril.
CapecitabineThe metabolism of Valsartan can be decreased when combined with Capecitabine.
CaptoprilValsartan may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Valsartan can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Valsartan.
CaroxazoneCaroxazone may increase the hypotensive activities of Valsartan.
CarprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Carprofen.
CarteololValsartan may increase the hypotensive activities of Carteolol.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Valsartan.
CarvedilolCarvedilol may increase the hypotensive activities of Valsartan.
CastanospermineThe risk or severity of adverse effects can be increased when Valsartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Valsartan is combined with Celecoxib.
CeliprololValsartan may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Valsartan can be increased when it is combined with Ceritinib.
CertoparinCertoparin may increase the hyperkalemic activities of Valsartan.
ChloroquineThe risk or severity of adverse effects can be increased when Valsartan is combined with Chloroquine.
ChlorothiazideValsartan may increase the hypotensive activities of Chlorothiazide.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Valsartan.
ChlorthalidoneValsartan may increase the hypotensive activities of Chlorthalidone.
CholecalciferolThe metabolism of Valsartan can be decreased when combined with Cholecalciferol.
CilazaprilValsartan may increase the hypotensive activities of Cilazapril.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Valsartan.
CiprofloxacinValsartan may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Valsartan.
ClevidipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Clevidipine.
ClonidineValsartan may increase the hypotensive activities of Clonidine.
ClonixinThe risk or severity of adverse effects can be increased when Valsartan is combined with Clonixin.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Valsartan.
ClotrimazoleThe metabolism of Valsartan can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Valsartan.
CryptenamineValsartan may increase the hypotensive activities of Cryptenamine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Valsartan.
CyclosporineValsartan may increase the hyperkalemic activities of Cyclosporine.
CyclosporineThe metabolism of Valsartan can be decreased when combined with Cyclosporine.
CyclothiazideValsartan may increase the hypotensive activities of Cyclothiazide.
D-LimoneneThe risk or severity of adverse effects can be increased when Valsartan is combined with D-Limonene.
DabrafenibThe serum concentration of Valsartan can be decreased when it is combined with Dabrafenib.
DalteparinDalteparin may increase the hyperkalemic activities of Valsartan.
DapagliflozinThe risk or severity of adverse effects can be increased when Valsartan is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Valsartan.
DapsoneThe metabolism of Dapsone can be decreased when combined with Valsartan.
DebrisoquinValsartan may increase the hypotensive activities of Debrisoquin.
DelavirdineThe metabolism of Valsartan can be decreased when combined with Delavirdine.
DeserpidineValsartan may increase the hypotensive activities of Deserpidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Dexmedetomidine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Valsartan.
DiazepamThe metabolism of Diazepam can be decreased when combined with Valsartan.
DiazoxideDiazoxide may increase the hypotensive activities of Valsartan.
DiclofenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Valsartan.
DiflunisalThe risk or severity of adverse effects can be increased when Valsartan is combined with Diflunisal.
DiltiazemValsartan may increase the hypotensive activities of Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Valsartan is combined with Dinutuximab.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Valsartan.
DipyridamoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Dipyridamole.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Valsartan.
DonepezilThe metabolism of Donepezil can be decreased when combined with Valsartan.
DopamineThe metabolism of Dopamine can be decreased when combined with Valsartan.
DorzolamideValsartan may increase the hypotensive activities of Dorzolamide.
DoxazosinValsartan may increase the hypotensive activities of Doxazosin.
DoxepinThe metabolism of Doxepin can be decreased when combined with Valsartan.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Valsartan.
DrospirenoneValsartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Droxicam.
DuloxetineValsartan may increase the orthostatic hypotensive activities of Duloxetine.
EfavirenzThe metabolism of Valsartan can be decreased when combined with Efavirenz.
EfonidipineValsartan may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Valsartan.
EltrombopagThe serum concentration of Valsartan can be increased when it is combined with Eltrombopag.
EmpagliflozinThe risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.
EnalaprilValsartan may increase the hypotensive activities of Enalapril.
EnalaprilatValsartan may increase the hypotensive activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Valsartan.
EpirizoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Valsartan.
EplerenoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Eplerenone.
EpoprostenolValsartan may increase the hypotensive activities of Epoprostenol.
EprosartanValsartan may increase the hypotensive activities of Eprosartan.
EsmololThe risk or severity of adverse effects can be increased when Valsartan is combined with Esmolol.
EstradiolThe metabolism of Estradiol can be decreased when combined with Valsartan.
EstroneThe metabolism of Estrone can be decreased when combined with Valsartan.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Valsartan.
Etacrynic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Valsartan is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Valsartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Valsartan is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Valsartan is combined with Etoricoxib.
EtravirineThe metabolism of Etravirine can be decreased when combined with Valsartan.
Evening primrose oilThe risk or severity of adverse effects can be increased when Valsartan is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Valsartan is combined with exisulind.
FelodipineValsartan may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenbufen.
FenoldopamValsartan may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Fenoprofen.
FloctafenineThe risk or severity of adverse effects can be increased when Valsartan is combined with Floctafenine.
FloxuridineThe metabolism of Valsartan can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Valsartan can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Valsartan.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Valsartan.
FlunixinThe risk or severity of adverse effects can be increased when Valsartan is combined with Flunixin.
FluorouracilThe metabolism of Valsartan can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Valsartan.
FlurbiprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Flurbiprofen.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Valsartan.
FluvoxamineThe metabolism of Valsartan can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Valsartan.
FosinoprilValsartan may increase the hypotensive activities of Fosinopril.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Valsartan.
FurazolidoneFurazolidone may increase the hypotensive activities of Valsartan.
FurosemideThe risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Valsartan.
GemfibrozilThe metabolism of Valsartan can be decreased when combined with Gemfibrozil.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Valsartan.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Valsartan.
GlipizideThe metabolism of Glipizide can be decreased when combined with Valsartan.
GlyburideThe metabolism of Glyburide can be decreased when combined with Valsartan.
GuanabenzValsartan may increase the hypotensive activities of Guanabenz.
GuanadrelValsartan may increase the hypotensive activities of Guanadrel.
GuanethidineValsartan may increase the hypotensive activities of Guanethidine.
GuanfacineValsartan may increase the hypotensive activities of Guanfacine.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Valsartan.
HalothaneThe metabolism of Halothane can be decreased when combined with Valsartan.
HeparinHeparin may increase the hyperkalemic activities of Valsartan.
HexamethoniumValsartan may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Valsartan.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Valsartan.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Valsartan.
HMPL-004The risk or severity of adverse effects can be increased when Valsartan is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Valsartan.
HydralazineValsartan may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Valsartan.
HydroflumethiazideValsartan may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Valsartan.
IbuprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Valsartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Valsartan is combined with Icatibant.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Valsartan.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Valsartan.
IloprostIloprost may increase the hypotensive activities of Valsartan.
ImatinibThe metabolism of Imatinib can be decreased when combined with Valsartan.
IndapamideValsartan may increase the hypotensive activities of Indapamide.
IndenololValsartan may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Valsartan can be decreased when combined with Indinavir.
indisulamThe metabolism of indisulam can be decreased when combined with Valsartan.
IndomethacinThe risk or severity of adverse effects can be increased when Valsartan is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Indoprofen.
IndoraminValsartan may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Valsartan.
IproniazidIproniazid may increase the hypotensive activities of Valsartan.
IrbesartanValsartan may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Valsartan.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Valsartan is combined with Isoxsuprine.
IsradipineValsartan may increase the hypotensive activities of Isradipine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Valsartan.
KebuzoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Kebuzone.
KetamineThe metabolism of Ketamine can be decreased when combined with Valsartan.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Valsartan.
KetoconazoleThe metabolism of Valsartan can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Valsartan is combined with Ketorolac.
LabetalolValsartan may increase the hypotensive activities of Labetalol.
LacidipineValsartan may increase the hypotensive activities of Lacidipine.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Valsartan.
LatanoprostValsartan may increase the hypotensive activities of Latanoprost.
LeflunomideThe risk or severity of adverse effects can be increased when Valsartan is combined with Leflunomide.
LeflunomideThe metabolism of Valsartan can be decreased when combined with Leflunomide.
LercanidipineValsartan may increase the hypotensive activities of Lercanidipine.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Valsartan.
LevobunololThe risk or severity of adverse effects can be increased when Valsartan is combined with Levobunolol.
LevodopaValsartan may increase the orthostatic hypotensive activities of Levodopa.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Valsartan.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Valsartan.
LisinoprilValsartan may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Valsartan.
LofexidineValsartan may increase the hypotensive activities of Lofexidine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Valsartan.
LornoxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Lornoxicam.
LosartanValsartan may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Valsartan can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Loxoprofen.
LumacaftorThe serum concentration of Valsartan can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Valsartan is combined with Lumiracoxib.
MacitentanValsartan may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Valsartan is combined with Magnesium salicylate.
ManidipineValsartan may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Valsartan is combined with Mannitol.
MasoprocolThe risk or severity of adverse effects can be increased when Valsartan is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Valsartan.
MecamylamineValsartan may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Mefenamic acid.
MelatoninThe metabolism of Melatonin can be decreased when combined with Valsartan.
MeloxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Meloxicam.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Valsartan.
MesalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Mesalazine.
MestranolThe metabolism of Mestranol can be decreased when combined with Valsartan.
MetamizoleThe risk or severity of adverse effects can be increased when Valsartan is combined with Metamizole.
MethadoneThe metabolism of Methadone can be decreased when combined with Valsartan.
MethazolamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Valsartan.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Valsartan.
MethyclothiazideThe risk or severity of adverse effects can be increased when Valsartan is combined with Methyclothiazide.
MethyldopaValsartan may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Valsartan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Valsartan.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Valsartan.
MetipranololValsartan may increase the hypotensive activities of Metipranolol.
MetolazoneValsartan may increase the hypotensive activities of Metolazone.
MetoprololValsartan may increase the hypotensive activities of Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Valsartan.
MibefradilValsartan may increase the hypotensive activities of Mibefradil.
MifepristoneThe serum concentration of Valsartan can be increased when it is combined with Mifepristone.
MinaprineMinaprine may increase the hypotensive activities of Valsartan.
MinoxidilValsartan may increase the hypotensive activities of Minoxidil.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Valsartan.
MoclobemideMoclobemide may increase the hypotensive activities of Valsartan.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Valsartan.
MoexiprilValsartan may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Valsartan.
MontelukastThe metabolism of Montelukast can be decreased when combined with Valsartan.
MoxonidineValsartan may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Nabumetone.
NadololValsartan may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Valsartan.
NaftifineThe risk or severity of adverse effects can be increased when Valsartan is combined with Naftifine.
NaproxenThe risk or severity of adverse effects can be increased when Valsartan is combined with Naproxen.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Valsartan.
NCX 4016The risk or severity of adverse effects can be increased when Valsartan is combined with NCX 4016.
NebivololValsartan may increase the hypotensive activities of Nebivolol.
NepafenacThe risk or severity of adverse effects can be increased when Valsartan is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nesiritide.
NetupitantThe metabolism of Netupitant can be decreased when combined with Valsartan.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Valsartan.
NialamideNialamide may increase the hypotensive activities of Valsartan.
NicardipineValsartan may increase the hypotensive activities of Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Valsartan.
NicorandilNicorandil may increase the hypotensive activities of Valsartan.
NicotineThe metabolism of Nicotine can be decreased when combined with Valsartan.
NifedipineThe risk or severity of adverse effects can be increased when Valsartan is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Valsartan is combined with Niflumic Acid.
NiguldipineValsartan may increase the hypotensive activities of Niguldipine.
NilvadipineValsartan may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimesulide.
NimodipineValsartan may increase the hypotensive activities of Nimodipine.
NisoldipineValsartan may increase the hypotensive activities of Nisoldipine.
NitrendipineValsartan may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Valsartan is combined with Nitroglycerin.
NitroprussideValsartan may increase the hypotensive activities of Nitroprusside.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Valsartan.
ObinutuzumabValsartan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Valsartan.
OlmesartanValsartan may increase the hypotensive activities of Olmesartan.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Valsartan.
OlopatadineThe risk or severity of adverse effects can be increased when Valsartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Olsalazine.
OmapatrilatValsartan may increase the hypotensive activities of Omapatrilat.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Valsartan.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Valsartan.
OrgoteinThe risk or severity of adverse effects can be increased when Valsartan is combined with Orgotein.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Valsartan.
OxaprozinThe risk or severity of adverse effects can be increased when Valsartan is combined with Oxaprozin.
OxprenololValsartan may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Oxyphenbutazone.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Valsartan.
PapaverineThe risk or severity of adverse effects can be increased when Valsartan is combined with Papaverine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Valsartan.
ParecoxibThe risk or severity of adverse effects can be increased when Valsartan is combined with Parecoxib.
PargylineValsartan may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Valsartan.
PenbutololValsartan may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Valsartan.
PentoliniumValsartan may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Valsartan.
PerindoprilValsartan may increase the hypotensive activities of Perindopril.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Valsartan.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Valsartan.
PhenelzinePhenelzine may increase the hypotensive activities of Valsartan.
PheniprazinePheniprazine may increase the hypotensive activities of Valsartan.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Valsartan.
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Valsartan.
PhenoxybenzamineValsartan may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Valsartan.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Valsartan.
PhentolamineValsartan may increase the hypotensive activities of Phentolamine.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Phenylbutazone.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Valsartan.
PimecrolimusThe risk or severity of adverse effects can be increased when Valsartan is combined with Pimecrolimus.
PinacidilValsartan may increase the hypotensive activities of Pinacidil.
PindololValsartan may increase the hypotensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Valsartan.
PirfenidoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Valsartan.
PiroxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Piroxicam.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Valsartan.
PivhydrazinePivhydrazine may increase the hypotensive activities of Valsartan.
PolythiazideValsartan may increase the hypotensive activities of Polythiazide.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Valsartan.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Valsartan.
PrazosinValsartan may increase the hypotensive activities of Prazosin.
PrimidonePrimidone may increase the hypotensive activities of Valsartan.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Valsartan.
ProguanilThe metabolism of Proguanil can be decreased when combined with Valsartan.
PromazineThe metabolism of Promazine can be decreased when combined with Valsartan.
PropacetamolThe risk or severity of adverse effects can be increased when Valsartan is combined with Propacetamol.
PropofolThe metabolism of Propofol can be decreased when combined with Valsartan.
PropranololValsartan may increase the hypotensive activities of Propranolol.
PTC299The risk or severity of adverse effects can be increased when Valsartan is combined with PTC299.
PyrimethamineThe metabolism of Valsartan can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Valsartan.
QuetiapineThe risk or severity of adverse effects can be increased when Valsartan is combined with Quetiapine.
QuinaprilValsartan may increase the hypotensive activities of Quinapril.
QuinidineThe metabolism of Quinidine can be decreased when combined with Valsartan.
QuinineQuinine may increase the hypotensive activities of Valsartan.
QuinineThe metabolism of Quinine can be decreased when combined with Valsartan.
RamiprilValsartan may increase the hypotensive activities of Ramipril.
RasagilineRasagiline may increase the hypotensive activities of Valsartan.
RemikirenValsartan may increase the hypotensive activities of Remikiren.
RescinnamineValsartan may increase the hypotensive activities of Rescinnamine.
ReserpineValsartan may increase the hypotensive activities of Reserpine.
ResveratrolThe risk or severity of adverse effects can be increased when Valsartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Valsartan.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Valsartan.
RifapentineThe metabolism of Valsartan can be increased when combined with Rifapentine.
RiociguatValsartan may increase the hypotensive activities of Riociguat.
RisperidoneValsartan may increase the hypotensive activities of Risperidone.
RituximabValsartan may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Valsartan is combined with Rofecoxib.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Valsartan.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Valsartan.
SafrazineSafrazine may increase the hypotensive activities of Valsartan.
SalicylamideThe risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Valsartan is combined with Salsalate.
SaprisartanValsartan may increase the hypotensive activities of Saprisartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Valsartan.
SelegilineSelegiline may increase the hypotensive activities of Valsartan.
SelegilineThe metabolism of Selegiline can be decreased when combined with Valsartan.
SelexipagValsartan may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Valsartan is combined with Seratrodast.
SertralineThe metabolism of Sertraline can be decreased when combined with Valsartan.
SildenafilSildenafil may increase the antihypertensive activities of Valsartan.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Valsartan.
SitaxentanValsartan may increase the hypotensive activities of Sitaxentan.
SorafenibThe metabolism of Valsartan can be decreased when combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Valsartan is combined with Sotalol.
SpiraprilValsartan may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Valsartan is combined with Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Valsartan is combined with SRT501.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Valsartan.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Valsartan.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Valsartan.
SulfasalazineThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulfasalazine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Valsartan.
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Valsartan.
SulindacThe risk or severity of adverse effects can be increased when Valsartan is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Valsartan.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Valsartan.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Valsartan.
TelmisartanValsartan may increase the hypotensive activities of Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Valsartan.
TemocaprilValsartan may increase the hypotensive activities of Temocapril.
TenoxicamThe risk or severity of adverse effects can be increased when Valsartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Valsartan is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Valsartan is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Valsartan.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Valsartan.
TeriflunomideThe serum concentration of Valsartan can be increased when it is combined with Teriflunomide.
TeriflunomideThe risk or severity of adverse effects can be increased when Valsartan is combined with Teriflunomide.
TerlipressinValsartan may increase the hypotensive activities of Terlipressin.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Valsartan.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Valsartan.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Valsartan.
ThiamylalThiamylal may increase the hypotensive activities of Valsartan.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Valsartan.
ThiopentalThiopental may increase the hypotensive activities of Valsartan.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Valsartan is combined with Tiaprofenic acid.
TiboloneValsartan may increase the hypotensive activities of Tibolone.
TicagrelorThe metabolism of Valsartan can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Valsartan can be decreased when combined with Ticlopidine.
TicrynafenValsartan may increase the hypotensive activities of Ticrynafen.
TimololValsartan may increase the hypotensive activities of Timolol.
TinzaparinTinzaparin may increase the hyperkalemic activities of Valsartan.
TizanidineThe risk or severity of adverse effects can be increased when Valsartan is combined with Tizanidine.
TolazolineValsartan may increase the hypotensive activities of Tolazoline.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Valsartan.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Valsartan is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Valsartan.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Valsartan.
TolvaptanTolvaptan may increase the hyperkalemic activities of Valsartan.
TorasemideValsartan may increase the hypotensive activities of Torasemide.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Valsartan.
TrandolaprilValsartan may increase the hypotensive activities of Trandolapril.
TranilastThe risk or severity of adverse effects can be increased when Valsartan is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Valsartan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Valsartan.
TravoprostValsartan may increase the hypotensive activities of Travoprost.
TreprostinilValsartan may increase the hypotensive activities of Treprostinil.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Valsartan.
TriamtereneThe risk or severity of adverse effects can be increased when Valsartan is combined with Triamterene.
TrichlormethiazideValsartan may increase the hypotensive activities of Trichlormethiazide.
TrimazosinValsartan may increase the hypotensive activities of Trimazosin.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Valsartan.
TrimethaphanValsartan may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Valsartan.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Valsartan.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Valsartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Valsartan is combined with Trisalicylate-choline.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Valsartan.
UdenafilUdenafil may increase the antihypertensive activities of Valsartan.
UnoprostoneValsartan may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Valsartan is combined with Valdecoxib.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Valsartan.
VardenafilVardenafil may increase the antihypertensive activities of Valsartan.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Valsartan.
VerapamilThe risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Valsartan.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Valsartan.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Valsartan.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Valsartan.
WarfarinThe metabolism of Warfarin can be decreased when combined with Valsartan.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Valsartan.
XylometazolineValsartan may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Valsartan.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Valsartan.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Valsartan.
ZaltoprofenThe risk or severity of adverse effects can be increased when Valsartan is combined with Zaltoprofen.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Valsartan.
ZileutonThe risk or severity of adverse effects can be increased when Valsartan is combined with Zileuton.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Valsartan.
ZomepiracThe risk or severity of adverse effects can be increased when Valsartan is combined with Zomepirac.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Valsartan.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Azizi M, Menard J, Bissery A, Guyenne TT, Bura-Riviere A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004 Dec;15(12):3126-33. [PubMed:15579516 ]
  3. Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, Ramjoue HP, Wood J: Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol. 1993 Oct;110(2):761-71. [PubMed:8242249 ]
  4. Shargorodsky M, Leibovitz E, Lubimov L, Gavish D, Zimlichman R: Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens. 2002 Dec;15(12):1087-91. [PubMed:12460705 ]
  5. de Gasparo M, Whitebread S: Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept. 1995 Nov 10;59(3):303-11. [PubMed:8577935 ]
  6. Siragy HM, El-Kersh MA, De Gasparo M, Webb RL, Carey RM: Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens. 2002 Jun;20(6):1157-63. [PubMed:12023686 ]
  7. Stanfield, Cindy L.;Germann, William J. (2009). Principles of Human Physiology (3rd ed.). Benjamin-Cummings Publishing Company. [ISBN:978-0321556660 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K: Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica. 2005 Jun;35(6):589-602. [PubMed:16192110 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611. doi: 10.1007/s10928-009-9139-3. Epub 2009 Nov 20. [PubMed:19936896 ]
  2. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers. 2009 Nov;6(11):1975-87. doi: 10.1002/cbdv.200900116. [PubMed:19937834 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):585-611. doi: 10.1007/s10928-009-9139-3. Epub 2009 Nov 20. [PubMed:19936896 ]
  2. Poirier A, Cascais AC, Funk C, Lave T: Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers. 2009 Nov;6(11):1975-87. doi: 10.1002/cbdv.200900116. [PubMed:19937834 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:40